Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.36 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.36 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.36 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23421553 | 0.89 | TLR8 (0.38) | TLR8TLR7PI4KAPI4K2BPI4K2A | |
| SCHEMBL18585619 | 0.86 | TLR8 (0.52) | TLR8TLR7 | |
| SCHEMBL18587553 | 0.85 | TLR8 (0.50) | TLR8TLR7PI4KAPI4K2BPI4K2A | |
| SCHEMBL20624057 | 0.85 | TLR8 (0.40) | TLR8TLR7 | |
| SCHEMBL23421950 | 0.84 | TLR8 (0.36) | TLR8TLR7CSNK1A1CSNK1DPRKCD | |
| SCHEMBL21976788 | 0.82 | TLR8 (0.39) | TLR8TLR7CSNK1A1CSNK1DPRKCD | |
| SCHEMBL23422321 | 0.81 | TLR8 (0.37) | TLR8TLR7 | |
| SCHEMBL18587589 | 0.80 | TLR8 (0.48) | TLR8TLR7CSNK1A1CSNK1DPRKCD | |
| SCHEMBL23113622 | 0.79 | TLR8 (0.34) | TLR8TLR7 | |
| SCHEMBL22451581 | 0.78 | SIGMAR1 (0.40) | TLR8SIGMAR1TLR7PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152215-A1 | Immunoconjugates Targeting CEA | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152215-A1 | Immunoconjugates Targeting CEA | CD47, FCGR3B, FCGR1A | TLR8 1941/4885SIGMAR1 3350/4885TLR7 797/4885 |
| US-20220143012-A1 | Macromolecule-Supported TLR Agonists | TLR8, TLR7, TLR9 | TLR8 1/4885SIGMAR1 261/4885TLR7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.